Control Empresarial De Capital Acquires 1,032,218 Shares of ProKidney Corp. (NASDAQ:PROK) Stock

ProKidney Corp. (NASDAQ:PROK) insider Control Empresarial De Capital bought 1,032,218 shares of the company’s stock in a transaction on Thursday, April 10th. The stock was bought at an average cost of $0.61 per share, with a total value of $629,652.98. Following the completion of the purchase, the insider now owns 72,592,325 shares of the company’s stock, valued at approximately $44,281,318.25. The trade was a 1.44 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

ProKidney Price Performance

Shares of NASDAQ:PROK opened at $0.71 on Wednesday. The company has a 50 day moving average of $1.08 and a 200-day moving average of $1.53. ProKidney Corp. has a one year low of $0.46 and a one year high of $4.44. The stock has a market cap of $207.84 million, a price-to-earnings ratio of -1.29 and a beta of 1.52.

ProKidney (NASDAQ:PROK) last announced its quarterly earnings results on Monday, March 17th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.03). The firm had revenue of $0.08 million during the quarter. Equities research analysts anticipate that ProKidney Corp. will post -0.57 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its holdings in ProKidney by 102.0% during the 3rd quarter. Geode Capital Management LLC now owns 2,203,934 shares of the company’s stock worth $4,232,000 after buying an additional 1,112,933 shares during the period. Hennion & Walsh Asset Management Inc. acquired a new position in shares of ProKidney during the 4th quarter worth approximately $961,000. Charles Schwab Investment Management Inc. raised its position in ProKidney by 150.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 749,718 shares of the company’s stock worth $1,439,000 after acquiring an additional 450,548 shares in the last quarter. State Street Corp lifted its stake in ProKidney by 16.2% in the 3rd quarter. State Street Corp now owns 1,428,318 shares of the company’s stock valued at $2,742,000 after purchasing an additional 198,836 shares during the last quarter. Finally, Bleichroeder LP raised its stake in ProKidney by 8.4% in the 4th quarter. Bleichroeder LP now owns 2,000,000 shares of the company’s stock valued at $3,380,000 after acquiring an additional 155,000 shares during the period. 51.59% of the stock is owned by institutional investors and hedge funds.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.